{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T14:35:25Z","timestamp":1792506925093,"version":"4.5.0"},"reference-count":310,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ageing Research Reviews"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.arr.2024.102229","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T00:52:14Z","timestamp":1707958334000},"page":"102229","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["Evolving therapeutic interventions for the management and treatment of Alzheimer\u2019s disease"],"prefix":"10.1016","volume":"95","author":[{"given":"Faizan","family":"Ahmad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anik","family":"Karan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashi","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navatha Shree","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaishnavi","family":"Sundar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Jayaraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudip","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"DeCoster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arr.2024.102229_bib1","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci10090628","article-title":"The possible neuroprotective effect of silymarin against aluminum chloride-prompted Alzheimer's-like disease in rats","volume":"10","author":"Aboelwafa","year":"2020","journal-title":"Brain Sci."},{"key":"10.1016\/j.arr.2024.102229_bib2","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/j.2042-7158.2011.01309.x","article-title":"Up-regulation of P-glycoprotein reduces intracellular accumulation of beta amyloid: investigation of P-glycoprotein as a novel therapeutic target for Alzheimer's disease","volume":"63","author":"Abuznait","year":"2011","journal-title":"J. Pharm. Pharm."},{"key":"10.1016\/j.arr.2024.102229_bib3","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.2174\/1381612822666160203142111","article-title":"Pharmacotherpy and Alzheimer\u2019s disease: The M-drugs (melatonin, minocycline, modafinil, and memantine) approach","volume":"22","author":"Adam Daulatzai","year":"2016","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.arr.2024.102229_bib4","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/agm2.12216","article-title":"A consolidated review on stem cell therapy for treatment and management of Alzheimer's disease","volume":"5","author":"Ahmad","year":"2022","journal-title":"Aging Med. (Milton)"},{"key":"10.1016\/j.arr.2024.102229_bib5","doi-asserted-by":"crossref","first-page":"47504","DOI":"10.1021\/acsomega.2c05609","article-title":"Preclinical models for Alzheimer's disease: past, present, and future approaches","volume":"7","author":"Akhtar","year":"2022","journal-title":"ACS Omega"},{"issue":"Suppl 1","key":"10.1016\/j.arr.2024.102229_bib6","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.neurobiolaging.2011.09.010","article-title":"Changes in cognition","volume":"32","author":"Albert","year":"2011","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.arr.2024.102229_bib7","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/jpi.12194","article-title":"Melatonin attenuates D-galactose-induced memory impairment, neuroinflammation and neurodegeneration via RAGE\/NF-K B\/JNK signaling pathway in aging mouse model","volume":"58","author":"Ali","year":"2015","journal-title":"J. Pineal Res."},{"key":"10.1016\/j.arr.2024.102229_bib8","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s11033-018-4499-7","article-title":"Stem cell therapy in Alzheimer's disease: possible benefits and limiting drawbacks","volume":"46","author":"Alipour","year":"2019","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.arr.2024.102229_bib9","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s13238-016-0338-6","article-title":"Human gut microbiota: the links with dementia development","volume":"8","author":"Alkasir","year":"2017","journal-title":"Protein Cell"},{"key":"10.1016\/j.arr.2024.102229_bib10","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3233\/JAD-210234","article-title":"Insulin Resistance as a Common Link Between Current Alzheimer's Disease Hypotheses","volume":"82","author":"Alves","year":"2021","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2024.102229_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2022.136528","article-title":"Activation of the sigma-1 receptor attenuates blood-brain barrier disruption by inhibiting amyloid deposition in Alzheimer's disease mice","volume":"774","author":"An","year":"2022","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.arr.2024.102229_bib12","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.nbd.2010.08.020","article-title":"L-type voltage-gated calcium channel blockade with isradipine as a therapeutic strategy for Alzheimer's disease","volume":"41","author":"Anekonda","year":"2011","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.arr.2024.102229_bib13","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3389\/fphar.2019.00665","article-title":"MicroRNAs in Alzheimer's Disease: Diagnostic Markers or Therapeutic Agents?","volume":"10","author":"Angelucci","year":"2019","journal-title":"Front Pharm."},{"key":"10.1016\/j.arr.2024.102229_bib14","doi-asserted-by":"crossref","first-page":"6412","DOI":"10.1038\/s41598-018-24501-0","article-title":"Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-beta","volume":"8","author":"Arndt","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.arr.2024.102229_bib15","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nrneurol.2017.185","article-title":"Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums","volume":"14","author":"Arnold","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.arr.2024.102229_bib16","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jama.2017.20373","article-title":"Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials","volume":"319","author":"Atri","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.arr.2024.102229_bib17","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1016\/j.xphs.2023.08.011","article-title":"Intramuscularly Administered PLGA Microparticles for Sustained Release of Rivastigmine: In Vitro, In Vivo and Histological Evaluation","volume":"112","author":"Avendano-Godoy","year":"2023","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.arr.2024.102229_bib18","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb2639","article-title":"Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer's disease","volume":"13","author":"Ayalon","year":"2021","journal-title":"Sci. Transl. Med"},{"key":"10.1016\/j.arr.2024.102229_bib19","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ejphar.2011.03.048","article-title":"Selective dihydropyiridine compounds facilitate the clearance of beta-amyloid across the blood-brain barrier","volume":"659","author":"Bachmeier","year":"2011","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.arr.2024.102229_bib20","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1017\/S0317167100044115","article-title":"Limbic predilection in Alzheimer dementia: is reactivated herpesvirus involved?","volume":"9","author":"Ball","year":"1982","journal-title":"Can. J. Neurol. Sci."},{"key":"10.1016\/j.arr.2024.102229_bib21","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s40120-020-00218-z","article-title":"CRISPR-Cas9: A Promising Genome Editing Therapeutic Tool for Alzheimer's Disease-A Narrative Review","volume":"9","author":"Barman","year":"2020","journal-title":"Neurol. Ther."},{"issue":"e057586","key":"10.1016\/j.arr.2024.102229_bib22","article-title":"Design of a patient-and investigator-blind, randomized, placebo-controlled study to evaluate efficacy, safety, and tolerability of bepranemab, UCB0107, in prodromal to mild Alzheimer\u2019s disease: The TOGETHER Study, AH0003","volume":"17","author":"Barton","year":"2021","journal-title":"Alzheimer'S. Dement."},{"key":"10.1016\/j.arr.2024.102229_bib23","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.5114\/aoms.2015.56342","article-title":"Brain-derived neurotrophic factor and its clinical implications","volume":"11","author":"Bathina","year":"2015","journal-title":"Arch. Med Sci."},{"issue":"6","key":"10.1016\/j.arr.2024.102229_bib24","doi-asserted-by":"crossref","first-page":"610","DOI":"10.2174\/1567205013666151221145445","article-title":"Evidence for mitochondrial UPR gene activation in familial and sporadic Alzheimer\u2019s disease","volume":"13","author":"Beck","year":"2016","journal-title":"Curr Alzheimer Res."},{"key":"10.1016\/j.arr.2024.102229_bib25","first-page":"940","article-title":"The effects of PPAR-gamma agonist pioglitazone on hippocampal cytokines, brain-derived neurotrophic factor, memory impairment, and oxidative stress status in lipopolysaccharide-treated rats","volume":"22","author":"Beheshti","year":"2019","journal-title":"Iran. J. Basic Med Sci."},{"key":"10.1016\/j.arr.2024.102229_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113337","article-title":"The road to precision medicine: Eliminating the \"One Size Fits All\" approach in Alzheimer's disease","volume":"153","author":"Behl","year":"2022","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.arr.2024.102229_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23158209","article-title":"Chronic-Antibiotics Induced Gut Microbiota Dysbiosis Rescues Memory Impairment and Reduces beta-Amyloid Aggregation in a Preclinical Alzheimer's Disease Model","volume":"23","author":"Bello-Medina","year":"2022","journal-title":"Int J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.arr.2024.102229_bib28","doi-asserted-by":"crossref","DOI":"10.1080\/17460441.2023.2266994","article-title":"Calcium channel blockers' contribution to overcoming Current drug discovery challenges in Alzheimer's disease","volume":"12","author":"Bernard","year":"2023","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.arr.2024.102229_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2021.462299","article-title":"Development of immunoprecipitation - two-dimensional liquid chromatography - mass spectrometry methodology as biomarker read-out to quantify phosphorylated tau in cerebrospinal fluid from Alzheimer disease patients","volume":"1651","author":"Bijttebier","year":"2021","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.arr.2024.102229_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.104707","article-title":"Advances and considerations in AD tau-targeted immunotherapy","volume":"134","author":"Bittar","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.arr.2024.102229_bib31","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/scrt440","article-title":"Neural stem cells genetically-modified to express neprilysin reduce pathology in Alzheimer transgenic models","volume":"5","author":"Blurton-Jones","year":"2014","journal-title":"Stem Cell Res Ther."},{"key":"10.1016\/j.arr.2024.102229_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2019.113112","article-title":"Neural stem cell therapy for neurovascular injury in Alzheimer's disease","volume":"324","author":"Boese","year":"2020","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.arr.2024.102229_bib33","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/BF00293315","article-title":"A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads","volume":"87","author":"Braak","year":"1994","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.arr.2024.102229_bib34","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3233\/JAD-2010-101245","article-title":"Endothelin-A receptor antagonists prevent amyloid-beta-induced increase in ETA receptor expression, oxidative stress, and cognitive impairment","volume":"23","author":"Briyal","year":"2011","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2024.102229_bib35","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000207505","article-title":"Lecanemab: Looking Before We Leap","author":"Burke","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.arr.2024.102229_bib36","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/scrt461","article-title":"Developing neural stem cell-based treatments for neurodegenerative diseases","volume":"5","author":"Byrne","year":"2014","journal-title":"Stem Cell Res Ther."},{"key":"10.1016\/j.arr.2024.102229_bib37","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.2147\/CIA.S46536","article-title":"Minocycline alleviates beta-amyloid protein and tau pathology via restraining neuroinflammation induced by diabetic metabolic disorder","volume":"8","author":"Cai","year":"2013","journal-title":"Clin. Inter. Aging"},{"key":"10.1016\/j.arr.2024.102229_bib38","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1080\/14656566.2018.1519022","article-title":"An evaluation of memantine ER + donepezil for the treatment of Alzheimer's disease","volume":"19","author":"Calhoun","year":"2018","journal-title":"Expert Opin. Pharm."},{"key":"10.1016\/j.arr.2024.102229_bib39","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jalz.2016.02.010","article-title":"Neuroinflammation in Alzheimer's disease: current evidence and future directions","volume":"12","author":"Calsolaro","year":"2016","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.arr.2024.102229_bib40","article-title":"Vaccine development to treat Alzheimer\u2019s disease neuropathology in APP\/PS1 transgenic mice","volume":"2012","author":"Carrera","year":"2012","journal-title":"Int. J. Alzheimer\u2019s\u00a0Dis."},{"key":"10.1016\/j.arr.2024.102229_bib41","doi-asserted-by":"crossref","first-page":"23","DOI":"10.17219\/acem\/61044","article-title":"Neuroprotective effects of erythropoietin on Alzheimer's dementia model in rats","volume":"26","author":"Cevik","year":"2017","journal-title":"Adv. Clin. Exp. Med."},{"key":"10.1016\/j.arr.2024.102229_bib42","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.mito.2020.11.008","article-title":"Exploring the role of mitochondrial proteins as molecular target in Alzheimer's disease","volume":"56","author":"Chadha","year":"2021","journal-title":"Mitochondrion"},{"key":"10.1016\/j.arr.2024.102229_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221810151","article-title":"Therapeutic potential of human stem cell implantation in Alzheimer's disease","volume":"22","author":"Chan","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.arr.2024.102229_bib44","article-title":"Hyperbaric oxygen ameliorates cognitive impairment in patients with Alzheimer's disease and amnestic mild cognitive impairment","volume":"6","author":"Chen","year":"2020","journal-title":"Alzheimers Dement (N\u00a0Y)"},{"key":"10.1016\/j.arr.2024.102229_bib45","article-title":"A possible mechanism for the enhanced toxicity of beta-amyloid protofibrils in Alzheimer's disease","volume":"120","author":"Chen","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.arr.2024.102229_bib46","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3233\/JAD-180209","article-title":"Effects of a 3-year multi-domain intervention with or without omega-3 supplementation on cognitive functions in older subjects with increased CAIDE dementia scores","volume":"64","author":"Chhetri","year":"2018","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2024.102229_bib47","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22094592","article-title":"Glutamatergic neurons differentiated from embryonic stem cells: an investigation of differentiation and associated diseases","volume":"22","author":"Chuang","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.arr.2024.102229_bib48","unstructured":"clinicalTrials.gov-014,Study of LM11A-31-BHS in Mild-moderate AD Patients."},{"key":"10.1016\/j.arr.2024.102229_bib49","unstructured":"clinicalTrials.gov-073,A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease."},{"key":"10.1016\/j.arr.2024.102229_bib50","unstructured":"clinicalTrials.gov-106, A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)."},{"key":"10.1016\/j.arr.2024.102229_bib51","unstructured":"clinicalTrials.gov-117,Riluzole in Mild Alzheimer's Disease."},{"key":"10.1016\/j.arr.2024.102229_bib52","unstructured":"clinicalTrials.gov-117a,Follow-up Study of Safety and Efficacy in Subjects Who Completed NEUROSTEM\u00ae Phase-I\/IIa Clinical Trial."},{"key":"10.1016\/j.arr.2024.102229_bib53","unstructured":"clinicalTrials.gov-130,Lomecel-B Infusion Versus Placebo in Patients With Alzheimer's Disease."},{"key":"10.1016\/j.arr.2024.102229_bib54","unstructured":"clinicalTrials.gov-134,A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD) (SKYLINE)."},{"key":"10.1016\/j.arr.2024.102229_bib55","unstructured":"clinicalTrials.gov-208,Safety and Exploratory Efficacy Study of NEUROSTEM\u00ae Versus Placebo in Patients With Alzheimer's Disease."},{"key":"10.1016\/j.arr.2024.102229_bib56","unstructured":"clinicalTrials.gov-218,The Safety and The Efficacy Evaluation of NEUROSTEM\u00ae-AD in Patients With Alzheimer's Disease."},{"key":"10.1016\/j.arr.2024.102229_bib57","unstructured":"clinicalTrials.gov-246,Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease."},{"key":"10.1016\/j.arr.2024.102229_bib58","unstructured":"clinicalTrials.gov-252,24 Months Safety and Efficacy Study of AADvac1 in Patients With Mild Alzheimer's Disease (ADAMANT)."},{"key":"10.1016\/j.arr.2024.102229_bib59","unstructured":"clinicalTrials.gov-276,Safety and Immunogenicity of Repeated Doses of ABvac40 in Patients With a-MCI or Vm-AD."},{"key":"10.1016\/j.arr.2024.102229_bib60","unstructured":"clinicalTrials.gov-287,Safety and Tolerability of PNT001 in Healthy Adults."},{"key":"10.1016\/j.arr.2024.102229_bib61","unstructured":"clinicalTrials.gov-306,Safety and Exploratory Efficacy Study of UCMSCs in Patients With Alzheimer's Disease (SEESUPAD)."},{"key":"10.1016\/j.arr.2024.102229_bib62","unstructured":"clinicalTrials.gov-334,A Study of V950 in People With Alzheimer Disease (V950-001 AM7)."},{"key":"10.1016\/j.arr.2024.102229_bib63","unstructured":"clinicalTrials.gov-348,Alzheimer's Disease Stem Cells Multiple Infusions."},{"key":"10.1016\/j.arr.2024.102229_bib64","unstructured":"clinicalTrials.gov-420,A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease (Autonomy)."},{"key":"10.1016\/j.arr.2024.102229_bib65","unstructured":"clinicalTrials.gov-474,Nicotinamide as an Early Alzheimer's Disease Treatment (NEAT)."},{"key":"10.1016\/j.arr.2024.102229_bib66","unstructured":"ClinicalTrials.gov-486,ClinicalTrials.gov. A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's Disease (MissionAD1)."},{"key":"10.1016\/j.arr.2024.102229_bib67","unstructured":"clinicalTrials.gov-528,Evaluating the Efficacy and Safety of Nilotinib BE in Subjects With Early Alzheimer's Disease (NILEAD)."},{"key":"10.1016\/j.arr.2024.102229_bib68","unstructured":"clinicalTrials.gov-536,A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Disease."},{"key":"10.1016\/j.arr.2024.102229_bib69","unstructured":"clinicalTrials.gov-557,Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease (TANGO)."},{"key":"10.1016\/j.arr.2024.102229_bib70","unstructured":"clinicalTrials.gov-573,Salsalate in Patients Mild to Moderate Alzheimer's Disease (SAL-AD)."},{"key":"10.1016\/j.arr.2024.102229_bib71","unstructured":"clinicalTrials.gov-577,Efficacy and Safety of Filgrastim in Alzheimer's Disease (FFAD)."},{"key":"10.1016\/j.arr.2024.102229_bib72","unstructured":"clinicalTrials.gov-616,A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD)."},{"key":"10.1016\/j.arr.2024.102229_bib73","unstructured":"clinicalTrials.gov-650,Safety, Tolerability, PK and PD of Posiphen\u00ae in Subjects With Early Alzheimer's Disease (DISCOVER)."},{"key":"10.1016\/j.arr.2024.102229_bib74","unstructured":"ClinicalTrials.gov-657,A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD) (CREAD 2)."},{"key":"10.1016\/j.arr.2024.102229_bib75","unstructured":"clinicalTrials.gov-689,Safety and Efficiency of Umbilical Cord-derived Mesenchymal Stem Cells(UC-MSC) in Patients With Alzheimer's Disease (SEMAD)."},{"key":"10.1016\/j.arr.2024.102229_bib76","unstructured":"clinicalTrials.gov-729,Single-Ascending-Dose Study of BIIB076 in Healthy Volunteers and Participants With Alzheimer's Disease."},{"key":"10.1016\/j.arr.2024.102229_bib77","unstructured":"clinicalTrials.gov-733,A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease."},{"key":"10.1016\/j.arr.2024.102229_bib78","unstructured":"clinicalTrials.gov-738,A Study to Evaluate the Safety and Efficacy of AstroStem in Treatment of Alzheimer's Disease."},{"key":"10.1016\/j.arr.2024.102229_bib79","unstructured":"ClinicalTrials.gov-747,A Study of Semorinemab in Patients With Moderate Alzheimer's Disease."},{"key":"10.1016\/j.arr.2024.102229_bib80","unstructured":"clinicalTrials.gov-786,A Study of RO6926496 in Healthy Volunteers."},{"key":"10.1016\/j.arr.2024.102229_bib81","unstructured":"clinicalTrials.gov-818,Clinical- and Immunological Activity, Safety and Tolerability of Different Doses \/ Formulations of AFFITOPE AD02 in Early Alzheimer's Disease."},{"key":"10.1016\/j.arr.2024.102229_bib82","unstructured":"clinicalTrials.gov-830,A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD)."},{"key":"10.1016\/j.arr.2024.102229_bib83","unstructured":"clinicalTrials.gov-860,Study With Lu AF87908 in Healthy Participants and Participants With Alzheimer's Disease."},{"key":"10.1016\/j.arr.2024.102229_bib84","unstructured":"clinicalTrials.gov-916,Anti-viral Therapy in Alzheimer's Disease."},{"key":"10.1016\/j.arr.2024.102229_bib85","unstructured":"clinicalTrials.gov-956,A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Participants With Early Alzheimer's Disease."},{"key":"10.1016\/j.arr.2024.102229_bib86","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.3390\/nu11102417","article-title":"Curcumin, hormesis and the nervous system","volume":"11","author":"Concetta Scuto","year":"2019","journal-title":"Nutrients"},{"key":"10.1016\/j.arr.2024.102229_bib87","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3389\/fnmol.2019.00110","article-title":"Editing the Central Nervous System Through CRISPR\/Cas9 Systems","volume":"12","author":"Cota-Coronado","year":"2019","journal-title":"Front Mol. Neurosci."},{"key":"10.1016\/j.arr.2024.102229_bib88","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/978-3-030-05542-4_2","article-title":"The Role of Biomarkers in Alzheimer's Disease Drug Development","volume":"1118","author":"Cummings","year":"2019","journal-title":"Adv. Exp. Med Biol."},{"key":"10.1016\/j.arr.2024.102229_bib89","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13195-021-00838-z","article-title":"Aducanumab produced a clinically meaningful benefit in association with amyloid lowering","volume":"13","author":"Cummings","year":"2021","journal-title":"Alzheimers Res Ther."},{"key":"10.1016\/j.arr.2024.102229_bib90","doi-asserted-by":"crossref","first-page":"362","DOI":"10.14283\/jpad.2023.30","article-title":"Lecanemab: Appropriate Use Recommendations","volume":"10","author":"Cummings","year":"2023","journal-title":"J. Prev. Alzheimers Dis."},{"key":"10.1016\/j.arr.2024.102229_bib91","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1038\/s41591-021-01455-x","article-title":"Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial","volume":"27","author":"Dam","year":"2021","journal-title":"Nat. Med"},{"key":"10.1016\/j.arr.2024.102229_bib92","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12504","article-title":"Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer's disease in rodent models","volume":"7","author":"Daniels","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.arr.2024.102229_bib93","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/jgs.16342","article-title":"Benefits and Harms of Statins in People with Dementia: A Systematic Review and Meta-Analysis","volume":"68","author":"Davis","year":"2020","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.arr.2024.102229_bib94","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/j.vaccine.2017.03.020","article-title":"MultiTEP platform-based DNA epitope vaccine targeting N-terminus of tau induces strong immune responses and reduces tau pathology in THY-Tau22 mice","volume":"35","author":"Davtyan","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.arr.2024.102229_bib95","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13195-019-0556-2","article-title":"Testing a MultiTEP-based combination vaccine to reduce Abeta and tau pathology in Tau22\/5xFAD bigenic mice.","volume":"11","author":"Davtyan","year":"2019","journal-title":"Alzheimers Res Ther."},{"key":"10.1016\/j.arr.2024.102229_bib96","doi-asserted-by":"crossref","DOI":"10.1038\/srep28912","article-title":"Alzheimer's disease Advax(CpG)- adjuvanted MultiTEP-based dual and single vaccines induce high-titer antibodies against various forms of tau and Abeta pathological molecules.","volume":"6","author":"Davtyan","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.arr.2024.102229_bib97","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0006-8993(94)01294-R","article-title":"Sigma receptor-mediated neuroprotection against glutamate toxicity in primary rat neuronal cultures","volume":"671","author":"DeCoster","year":"1995","journal-title":"Brain Res"},{"key":"10.1016\/j.arr.2024.102229_bib98","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/j.clinph.2019.06.007","article-title":"Sleep deprivation and Modafinil affect cortical sources of resting state electroencephalographic rhythms in healthy young adults","volume":"130","author":"Del Percio","year":"2019","journal-title":"Clin. Neurophysiol."},{"key":"10.1016\/j.arr.2024.102229_bib99","doi-asserted-by":"crossref","DOI":"10.3390\/biom9020056","article-title":"Formulations of Curcumin Nanoparticles for Brain Diseases","volume":"9","author":"Del Prado-Audelo","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.arr.2024.102229_bib100","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/j.apsb.2021.12.009","article-title":"Pharmacological modulation of autophagy for Alzheimer's disease therapy: Opportunities and obstacles","volume":"12","author":"Deng","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.arr.2024.102229_bib101","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13024-019-0333-5","article-title":"The neuropathological diagnosis of Alzheimer's disease","volume":"14","author":"DeTure","year":"2019","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.arr.2024.102229_bib102","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cct.2018.05.019","article-title":"Lithium Treatment for Agitation in Alzheimer's disease (Lit-AD): Clinical rationale and study design","volume":"71","author":"Devanand","year":"2018","journal-title":"Conte Clin. Trials"},{"key":"10.1016\/j.arr.2024.102229_bib103","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease","volume":"370","author":"Doody","year":"2014","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.arr.2024.102229_bib104","doi-asserted-by":"crossref","first-page":"32691","DOI":"10.1073\/pnas.1908658117","article-title":"Clinically approved IVIg delivered to the hippocampus with focused ultrasound promotes neurogenesis in a model of Alzheimer's disease","volume":"117","author":"Dubey","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.arr.2024.102229_bib105","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00401-018-1880-5","article-title":"MicroRNA-132 provides neuroprotection for tauopathies via multiple signaling pathways","volume":"136","author":"El Fatimy","year":"2018","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.arr.2024.102229_bib106","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/B978-0-12-815461-8.00002-5","article-title":"Curcumin: Historical background, chemistry, pharmacological action, and potential therapeutic value","author":"Farooqui","year":"2019","journal-title":"Curcumin Neurol. Psychiatr. Disord."},{"key":"10.1016\/j.arr.2024.102229_bib107","unstructured":"FDA.gov, 2021. Aducanumab-FDA."},{"key":"10.1016\/j.arr.2024.102229_bib108","unstructured":"FDA.gov, 2023. Lecanemab-FDA."},{"key":"10.1016\/j.arr.2024.102229_bib109","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.trci.2019.09.019","article-title":"Prevention of Alzheimer's disease by treating mild cognitive impairment with combinations chosen from eight available drugs","volume":"5","author":"Fessel","year":"2019","journal-title":"Alzheimers Dement (N. Y"},{"key":"10.1016\/j.arr.2024.102229_bib110","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jgeb.2018.09.002","article-title":"Recent advances in stem cells therapy: A focus on cancer, Parkinson's and Alzheimer's","volume":"16","author":"Fleifel","year":"2018","journal-title":"J. Genet Eng. Biotechnol."},{"key":"10.1016\/j.arr.2024.102229_bib111","doi-asserted-by":"crossref","first-page":"796","DOI":"10.4088\/JCP.10m06708","article-title":"A randomized, double-blind, placebo-controlled trial of modafinil for the treatment of apathy in individuals with mild-to-moderate Alzheimer's disease","volume":"73","author":"Frakey","year":"2012","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.arr.2024.102229_bib112","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s13311-014-0320-z","article-title":"Promoting autophagic clearance: viable therapeutic targets in Alzheimer's disease","volume":"12","author":"Friedman","year":"2015","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.arr.2024.102229_bib113","doi-asserted-by":"crossref","first-page":"4430","DOI":"10.1523\/JNEUROSCI.0420-17.2017","article-title":"Aducanumab Therapy Ameliorates Calcium Overload in a Mouse Model of Alzheimer's Disease","volume":"37","author":"Gamage","year":"2017","journal-title":"J. Neurosci."},{"key":"10.1016\/j.arr.2024.102229_bib114","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1016\/j.ymthe.2022.07.001","article-title":"A truncated reverse transcriptase enhances prime editing by split AAV vectors","volume":"30","author":"Gao","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.arr.2024.102229_bib115","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/13543784.2017.1267726","article-title":"AVP-786 for the treatment of agitation in dementia of the Alzheimer's type","volume":"26","author":"Garay","year":"2017","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.arr.2024.102229_bib116","first-page":"1471","article-title":"Ginkgo biloba extract improves cognitive function and increases neurogenesis by reducing Abeta pathology in 5xFAD mice","volume":"13","author":"Ge","year":"2021","journal-title":"Am. J. Transl. Res"},{"key":"10.1016\/j.arr.2024.102229_bib117","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23158733","article-title":"Lithium Enhances Hippocampal Glucose Metabolism in an In Vitro Mice Model of Alzheimer's Disease","volume":"23","author":"Gherardelli","year":"2022","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.arr.2024.102229_bib118","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2147\/CIA.S155145","article-title":"Genome-editing applications of CRISPR-Cas9 to promote in vitro studies of Alzheimer's disease.","volume":"13","author":"Giau","year":"2018","journal-title":"Clin. Inter. Aging"},{"key":"10.1016\/j.arr.2024.102229_bib119","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2147\/JEP.S262352","article-title":"Experimental disease-modifying agents for frontotemporal lobar degeneration","author":"Giunta","year":"2021","journal-title":"J. Exp. Pharmacol."},{"key":"10.1016\/j.arr.2024.102229_bib120","doi-asserted-by":"crossref","first-page":"12764","DOI":"10.1523\/JNEUROSCI.3566-09.2009","article-title":"New insights in the biology of BDNF synthesis and release: implications in CNS function","volume":"29","author":"Greenberg","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.arr.2024.102229_bib121","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s40267-022-00944-4","article-title":"Aducanumab: A review of the first approved amyloid-targeting antibody for Alzheimer\u2019s disease","volume":"38","author":"Grover","year":"2022","journal-title":"Drugs Ther. Perspect."},{"key":"10.1016\/j.arr.2024.102229_bib122","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24091748","article-title":"Silymarin's Inhibition and Treatment Effects for Alzheimer's Disease","volume":"24","author":"Guo","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.arr.2024.102229_bib123","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.1831","article-title":"Memantine, Donepezil, or Combination Therapy-What is the best therapy for Alzheimer's Disease? A Network Meta-Analysis.","volume":"10","author":"Guo","year":"2020","journal-title":"Brain Behav."},{"key":"10.1016\/j.arr.2024.102229_bib124","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41582-019-0307-9","article-title":"In search of an anti-inflammatory drug for Alzheimer disease","volume":"16","author":"Gyengesi","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.arr.2024.102229_bib125","first-page":"31925","article-title":"Aducanumab, a Novel Anti-Amyloid Monoclonal Antibody, for the Treatment of Alzheimer's Disease: A Comprehensive Review","volume":"10","author":"Haddad","year":"2022","journal-title":"Health Psychol. Res"},{"key":"10.1016\/j.arr.2024.102229_bib126","article-title":"A precision medicine framework using artificial intelligence for the identification and confirmation of genomic biomarkers of response to an Alzheimer's disease therapy: Analysis of the blarcamesine (ANAVEX2-73) Phase 2a clinical study","volume":"6","author":"Hampel","year":"2020","journal-title":"Alzheimers Dement (N. Y"},{"key":"10.1016\/j.arr.2024.102229_bib127","first-page":"18","article-title":"Neuroprotective Potentials of Marine Algae and Their Bioactive Metabolites: Pharmacological Insights and Therapeutic Advances","author":"Hannan","year":"2020","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.arr.2024.102229_bib128","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","article-title":"The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics","volume":"297","author":"Hardy","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.arr.2024.102229_bib129","doi-asserted-by":"crossref","first-page":"328","DOI":"10.15252\/emmm.201505846","article-title":"Therapeutic correction of ApoER2 splicing in Alzheimer's disease mice using antisense oligonucleotides","volume":"8","author":"Hinrich","year":"2016","journal-title":"EMBO Mol. Med"},{"key":"10.1016\/j.arr.2024.102229_bib130","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/1742-2094-8-171","article-title":"Neuroinflammation in Alzheimer's disease wanes with age","volume":"8","author":"Hoozemans","year":"2011","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.arr.2024.102229_bib131","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-51809-2","article-title":"A MultiTEP platform-based epitope vaccine targeting the phosphatase activating domain (PAD) of tau: therapeutic efficacy in PS19 mice","volume":"9","author":"Hovakimyan","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.arr.2024.102229_bib132","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41541-022-00544-3","article-title":"Immunogenicity of MultiTEP platform technology-based Tau vaccine in non-human primates","volume":"7","author":"Hovakimyan","year":"2022","journal-title":"NPJ Vaccin."},{"key":"10.1016\/j.arr.2024.102229_bib133","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jamaneurol.2019.3762","article-title":"Minocycline at 2 Different Dosages vs Placebo for Patients With Mild Alzheimer Disease: A Randomized Clinical Trial","volume":"77","author":"Howard","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.arr.2024.102229_bib134","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jamaneurol.2019.3762","article-title":"Minocycline in Alzheimer Disease Efficacy (MADE) Trialist Group. Minocycline at 2 different dosages vs placebo for patients with mild Alzheimer disease: a randomized clinical trial","volume":"77","author":"Howard","year":"2019","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.arr.2024.102229_bib135","doi-asserted-by":"crossref","unstructured":"Howard, R., Zubko, O., Gray, R., Bradley, R., Harper, E., Kelly, L., Pank, L., O\u2032Brien, J., Fox, C., Tabet, N., Livingston, G., Bentham, P., McShane, R., Burns, A., Ritchie, C., Reeves, S., Lovestone, S., Ballard, C., Noble, W., Wilcock, G., Nilforooshan, R., 2020b. Minocycline 200mg or 400mg versus placebo for mild Alzheimer's disease: the MADE Phase II, three-arm RCT, Southampton (UK).","DOI":"10.3310\/eme07020"},{"key":"10.1016\/j.arr.2024.102229_bib136","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12929-019-0609-7","article-title":"Clinical trials of new drugs for Alzheimer disease","volume":"27","author":"Huang","year":"2020","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.arr.2024.102229_bib137","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s12276-022-00754-8","article-title":". gamma-Secretase in Alzheimer's disease","volume":"54","author":"Hur","year":"2022","journal-title":"Exp. Mol. Med"},{"key":"10.1016\/j.arr.2024.102229_bib138","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1177\/0960327120960775","article-title":"Sildenafil ameliorates Alzheimer disease via the modulation of vascular endothelial growth factor and vascular cell adhesion molecule-1 in rats","volume":"40","author":"Ibrahim","year":"2021","journal-title":"Hum. Exp. Toxicol."},{"key":"10.1016\/j.arr.2024.102229_bib139","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13550280701802543","article-title":"Herpes simplex virus type 1 and Alzheimer's disease: the autophagy connection","volume":"14","author":"Itzhaki","year":"2008","journal-title":"J. Neurovirol"},{"key":"10.1016\/j.arr.2024.102229_bib140","doi-asserted-by":"crossref","first-page":"979","DOI":"10.3233\/JAD-160152","article-title":"Microbes and Alzheimer's Disease","volume":"51","author":"Itzhaki","year":"2016","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2024.102229_bib141","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1248\/bpb.30.698","article-title":"Nilvadipine prevents the impairment of spatial memory induced by cerebral ischemia combined with beta-amyloid in rats","volume":"30","author":"Iwasaki","year":"2007","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.arr.2024.102229_bib142","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40478-019-0664-z","article-title":"A walk through tau therapeutic strategies","volume":"7","author":"Jadhav","year":"2019","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.arr.2024.102229_bib143","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.neuron.2010.11.034","article-title":"Local presynaptic activity gates homeostatic changes in presynaptic function driven by dendritic BDNF synthesis","volume":"68","author":"Jakawich","year":"2010","journal-title":"Neuron"},{"key":"10.1016\/j.arr.2024.102229_bib144","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/5548630","article-title":"Extracellular Vesicles Released from Neprilysin Gene-Modified Human Umbilical Cord-Derived Mesenchymal Stem Cell Enhance Therapeutic Effects in an Alzheimer's Disease Animal Model","volume":"2021","author":"Jeong","year":"2021","journal-title":"Stem Cells Int"},{"key":"10.1016\/j.arr.2024.102229_bib145","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s40265-021-01546-6","article-title":"Current Status of Clinical Trials on Tau Immunotherapies","volume":"81","author":"Ji","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.arr.2024.102229_bib146","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.neuroscience.2015.11.016","article-title":"Evaluation of liposomal nanocarriers loaded with ETB receptor agonist, IRL-1620, using cell-based assays","volume":"312","author":"Joshi","year":"2016","journal-title":"Neuroscience"},{"key":"10.1016\/j.arr.2024.102229_bib147","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.dadm.2016.11.004","article-title":"Assessing quality of life in Alzheimer's disease: Implications for clinical trials","volume":"6","author":"Kahle-Wrobleski","year":"2017","journal-title":"Alzheimers Dement (Amst. )"},{"key":"10.1016\/j.arr.2024.102229_bib148","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/cns.13095","article-title":"Treatment of dementia and mild cognitive impairment with or without cerebrovascular disease: Expert consensus on the use of Ginkgo biloba extract, EGb 761((R)","volume":"25","author":"Kandiah","year":"2019","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.arr.2024.102229_bib149","doi-asserted-by":"crossref","first-page":"12267","DOI":"10.1002\/jcp.27972","article-title":"CRISPR\/Cas9 technology as a potent molecular tool for gene therapy","volume":"234","author":"Karimian","year":"2019","journal-title":"J. Cell Physiol."},{"key":"10.1016\/j.arr.2024.102229_bib150","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118165","article-title":"CRISPR\/Cas9 novel therapeutic road for the treatment of neurodegenerative diseases","volume":"259","author":"Karimian","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.arr.2024.102229_bib151","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/S1474-4422(20)30231-3","article-title":"Brain insulin resistance in Alzheimer's disease and related disorders: mechanisms and therapeutic approaches","volume":"19","author":"Kellar","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.arr.2024.102229_bib152","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0306-4522(99)00042-1","article-title":"Alterations in the ryanodine receptor calcium release channel correlate with Alzheimer's disease neurofibrillary and beta-amyloid pathologies","volume":"92","author":"Kelliher","year":"1999","journal-title":"Neuroscience"},{"key":"10.1016\/j.arr.2024.102229_bib153","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/gps.2735","article-title":"Apolipoprotein E genotype-specific short-term cognitive benefits of treatment with the antihypertensive nilvadipine in Alzheimer's patients--an open-label trial.","volume":"27","author":"Kennelly","year":"2012","journal-title":"Int J. Geriatr. Psychiatry"},{"key":"10.1016\/j.arr.2024.102229_bib154","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/awad159","article-title":"The amyloid cascade hypothesis: an updated critical review","author":"Kepp","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.arr.2024.102229_bib155","article-title":"Alzheimer's disease diagnosis and management: Perspectives from around the world","volume":"14","author":"Kerwin","year":"2022","journal-title":"Alzheimers Dement (Amst."},{"key":"10.1016\/j.arr.2024.102229_bib156","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1080\/13543784.2018.1483334","article-title":"The role of 5 HT6-receptor antagonists in Alzheimer's disease: an update","volume":"27","author":"Khoury","year":"2018","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.arr.2024.102229_bib157","doi-asserted-by":"crossref","first-page":"4128","DOI":"10.1073\/pnas.1422448112","article-title":"Adult hippocampal neural stem and progenitor cells regulate the neurogenic niche by secreting VEGF","volume":"112","author":"Kirby","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.arr.2024.102229_bib158","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0006-8993(95)01103-X","article-title":"Role of calcium in sigma-mediated neuroprotection in rat primary cortical neurons","volume":"704","author":"Klette","year":"1995","journal-title":"Brain Res"},{"key":"10.1016\/j.arr.2024.102229_bib159","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0006-8993(97)00142-X","article-title":"Neuroprotective sigma ligands attenuate NMDA and trans-ACPD-induced calcium signaling in rat primary neurons","volume":"756","author":"Klette","year":"1997","journal-title":"Brain Res"},{"key":"10.1016\/j.arr.2024.102229_bib160","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/alz.12286","article-title":"ENGAGE and EMERGE: Truth and consequences?","volume":"17","author":"Kuller","year":"2021","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.arr.2024.102229_bib161","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1021\/acs.jafc.8b04514","article-title":"Ginkgolide a prevents the amyloid-beta-induced depolarization of cortical neurons","volume":"67","author":"Kuo","year":"2019","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.arr.2024.102229_bib162","doi-asserted-by":"crossref","DOI":"10.3390\/biom13030453","article-title":"The amyloid cascade hypothesis in Alzheimer's disease: should we change our thinking?","volume":"13","author":"Kurkinen","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.arr.2024.102229_bib163","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1750-1326-6-17","article-title":"Differential regulation of BACE1 expression by oxidative and nitrosative signals","volume":"6","author":"Kwak","year":"2011","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.arr.2024.102229_bib164","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120420","article-title":"Anti-abeta oligomer IgG and surface sialic acid in intravenous immunoglobulin: measurement and correlation with clinical outcomes in Alzheimer's disease treatment","volume":"10","author":"Kwon","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.arr.2024.102229_bib165","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1600-079X.1999.tb00575.x","article-title":"Melatonin affects the metabolism of the beta-amyloid precursor protein in different cell types","volume":"26","author":"Lahiri","year":"1999","journal-title":"J. Pineal Res"},{"key":"10.1016\/j.arr.2024.102229_bib166","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1600-079X.2004.00121.x","article-title":"Dietary supplementation with melatonin reduces levels of amyloid beta-peptides in the murine cerebral cortex","volume":"36","author":"Lahiri","year":"2004","journal-title":"J. Pineal Res"},{"key":"10.1016\/j.arr.2024.102229_bib167","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.tem.2016.12.001","article-title":"ApoE, ApoE Receptors, and the Synapse in Alzheimer's Disease","volume":"28","author":"Lane-Donovan","year":"2017","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.arr.2024.102229_bib168","article-title":"PostGraduate open-label rollover study: evaluation of subcutaneous gantenerumab long-term safety, tolerability, and efficacy in participants with Alzheimer\u2019s disease (P6-3.002)","author":"Lane","year":"2022","journal-title":"AAN Enterprises"},{"key":"10.1016\/j.arr.2024.102229_bib169","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1600-079X.2011.00965.x","article-title":"Interleukin-6 autocrine signaling mediates melatonin MT1\/2 receptor-induced STAT3 Tyr705 phosphorylation","volume":"52","author":"Lau","year":"2012","journal-title":"J. Pineal Res."},{"key":"10.1016\/j.arr.2024.102229_bib170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002660","article-title":"Nilvadipine in mild to moderate Alzheimer disease: a randomised controlled trial","volume":"15","author":"Lawlor","year":"2018","journal-title":"PLoS Med"},{"key":"10.1016\/j.arr.2024.102229_bib171","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13195-021-00809-4","article-title":"A comparative study of the effects of Aducanumab and scanning ultrasound on amyloid plaques and behavior in the APP23 mouse model of Alzheimer disease","volume":"13","author":"Leinenga","year":"2021","journal-title":"Alzheimers Res Ther."},{"key":"10.1016\/j.arr.2024.102229_bib172","doi-asserted-by":"crossref","first-page":"19226","DOI":"10.3390\/ijms151019226","article-title":"Stem cell treatment for Alzheimer's disease","volume":"15","author":"Li","year":"2014","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.arr.2024.102229_bib173","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/jnc.15031","article-title":"Gut microbiota regulate cognitive deficits and amyloid deposition in a model of Alzheimer's disease","volume":"155","author":"Li","year":"2020","journal-title":"J. Neurochem"},{"key":"10.1016\/j.arr.2024.102229_bib174","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s40120-021-00282-z","article-title":"The development of pharmacological therapies for Alzheimer's disease","volume":"10","author":"Lin","year":"2021","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.arr.2024.102229_bib175","doi-asserted-by":"crossref","first-page":"787","DOI":"10.4252\/wjsc.v12.i8.787","article-title":"Stem cell therapy for Alzheimer's disease","volume":"12","author":"Liu","year":"2020","journal-title":"World J. Stem Cells"},{"key":"10.1016\/j.arr.2024.102229_bib176","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jcis.2019.05.066","article-title":"Quercetin-modified gold-palladium nanoparticles as a potential autophagy inducer for the treatment of Alzheimer's disease","volume":"552","author":"Liu","year":"2019","journal-title":"J. Colloid Interface Sci."},{"issue":"1","key":"10.1016\/j.arr.2024.102229_bib177","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40035-017-0092-6","article-title":"Endoplasmic reticulum-mitochondria tethering in neurodegenerative diseases","volume":"6","author":"Liu","year":"2017","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.arr.2024.102229_bib178","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1586\/ern.11.132","article-title":"Use of memantine for the treatment of dementia","volume":"11","author":"Lo","year":"2011","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.arr.2024.102229_bib179","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1532-5415.2004.52109.x","article-title":"A randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer's disease","volume":"52","author":"Loeb","year":"2004","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.arr.2024.102229_bib180","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1742-2094-10-70","article-title":"Intravenous immunoglobulin and Alzheimer's disease: what now?","volume":"10","author":"Loeffler","year":"2013","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.arr.2024.102229_bib181","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.trci.2019.09.014","article-title":"A genetic signature including apolipoprotein Eepsilon4 potentiates the risk of herpes simplex-associated Alzheimer's disease","volume":"5","author":"Lopatko Lindman","year":"2019","journal-title":"Alzheimers Dement (N\u00a0Y)"},{"key":"10.1016\/j.arr.2024.102229_bib182","first-page":"CD000147","article-title":"Nimodipine for primary degenerative, mixed and vascular dementia","author":"Lopez-Arrieta","year":"2002","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.arr.2024.102229_bib183","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241411450","article-title":"Repositioning of anti-diabetic drugs against dementia: insight from molecular perspectives to clinical trials","volume":"24","author":"Mantik","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.arr.2024.102229_bib184","doi-asserted-by":"crossref","first-page":"S167","DOI":"10.37765\/ajmc.2020.88481","article-title":"Current and evolving treatment strategies for the Alzheimer disease continuum","volume":"26","author":"Marasco","year":"2020","journal-title":"Am. J. Manag Care"},{"key":"10.1016\/j.arr.2024.102229_bib185","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s00702-021-02457-2","article-title":"Challenges of repurposing tetracyclines for the treatment of Alzheimer's and Parkinson's disease","volume":"129","author":"Markulin","year":"2022","journal-title":"J. Neural Transm. (Vienna)"},{"key":"10.1016\/j.arr.2024.102229_bib186","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.neuint.2017.02.006","article-title":"Neural stem cell therapy for neurodegenerative disorders: The role of neurotrophic support","volume":"106","author":"Marsh","year":"2017","journal-title":"Neurochem Int"},{"key":"10.1016\/j.arr.2024.102229_bib187","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1046\/j.1471-4159.2003.01654.x","article-title":"Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease","volume":"85","author":"Matsubara","year":"2003","journal-title":"J. Neurochem."},{"key":"10.1016\/j.arr.2024.102229_bib188","unstructured":"Matsumoto, Y., 2012. Dna vaccine for alzheimer's disease. Google Patents."},{"key":"10.1016\/j.arr.2024.102229_bib189","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0075203","article-title":"Development of a new DNA vaccine for Alzheimer disease targeting a wide range of abeta species and amyloidogenic peptides","volume":"8","author":"Matsumoto","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.arr.2024.102229_bib190","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13195-022-01124-2","article-title":"Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study","volume":"14","author":"McDade","year":"2022","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.arr.2024.102229_bib191","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/acn3.443","article-title":"Human neural stem cell transplantation into the corpus callosum of Alzheimer's mice","volume":"4","author":"McGinley","year":"2017","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.arr.2024.102229_bib192","doi-asserted-by":"crossref","first-page":"379","DOI":"10.5966\/sctm.2015-0103","article-title":"Human cortical neural stem cells expressing insulin-like growth factor-I: a novel cellular therapy for Alzheimer's disease","volume":"5","author":"McGinley","year":"2016","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.arr.2024.102229_bib193","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.tem.2010.05.005","article-title":"Alzheimer's disease: brain expression of a metabolic disorder?","volume":"21","author":"Merlo","year":"2010","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.arr.2024.102229_bib194","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12915-021-01214-x","article-title":"CRISPR\/Cas9-mediated gene knockout and interallelic gene conversion in human induced pluripotent stem cells using non-integrative bacteriophage-chimeric retrovirus-like particles","volume":"20","author":"Mianne","year":"2022","journal-title":"BMC Biol."},{"key":"10.1016\/j.arr.2024.102229_bib195","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1124\/dmd.121.000417","article-title":"Absorption, distribution, metabolism, and excretion of US food and drug administration-approved antisense oligonucleotide drugs","volume":"50","author":"Migliorati","year":"2022","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.arr.2024.102229_bib196","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in Early Alzheimer's Disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.arr.2024.102229_bib197","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s12291-018-0804-4","article-title":"Gene editing in clinical practice: where are we?","volume":"34","author":"Mittal","year":"2019","journal-title":"Indian J. Clin. Biochem"},{"key":"10.1016\/j.arr.2024.102229_bib198","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/gps.3846","article-title":"A multicenter, blinded, randomized, factorial controlled trial of doxycycline and rifampin for treatment of Alzheimer's disease: the DARAD trial","volume":"28","author":"Molloy","year":"2013","journal-title":"Int J. Geriatr. Psychiatry"},{"key":"10.1016\/j.arr.2024.102229_bib199","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1002\/alz.12321","article-title":"Visualization of neurofibrillary tangle maturity in Alzheimer's disease: A clinicopathologic perspective for biomarker research","volume":"17","author":"Moloney","year":"2021","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.arr.2024.102229_bib200","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/d41573-020-00217-7","article-title":"Failure of first anti-tau antibody in Alzheimer disease highlights risks of history repeating","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.arr.2024.102229_bib201","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/s41591-023-02326-3","article-title":"Tau-targeting antisense oligonucleotide MAPT(Rx) in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial.","volume":"29","author":"Mummery","year":"2023","journal-title":"Nat. Med"},{"key":"10.1016\/j.arr.2024.102229_bib202","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.physbeh.2015.02.003","article-title":"Modafinil as a cognitive enhancer of spatial working memory in rats","volume":"142","author":"Murphy","year":"2015","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.arr.2024.102229_bib203","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00335-019-09807-2","article-title":"Uses for humanised mouse models in precision medicine for neurodegenerative disease","volume":"30","author":"Nair","year":"2019","journal-title":"Mamm. Genome"},{"key":"10.1016\/j.arr.2024.102229_bib204","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40478-018-0515-3","article-title":"White matter changes in Alzheimer's disease: a focus on myelin and oligodendrocytes","volume":"6","author":"Nasrabady","year":"2018","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.arr.2024.102229_bib205","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.neuron.2018.11.040","article-title":"Harnessing genetic complexity to enhance translatability of Alzheimer's disease mouse models: a path toward precision medicine","volume":"101","author":"Neuner","year":"2019","journal-title":"Neuron"},{"key":"10.1016\/j.arr.2024.102229_bib206","article-title":"Open RoAD: Design and baseline characteristics of an open-label rollover study evaluating long-term safety and tolerability of subcutaneous gantenerumab in participants with early Alzheimer\u2019s disease","volume":"19","author":"Neve","year":"2023","journal-title":"Alzheimer's\u00a0Dement."},{"key":"10.1016\/j.arr.2024.102229_bib207","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.733857","article-title":"Amyloid-beta and alpha-synuclein immunotherapy: from experimental studies to clinical trials","volume":"15","author":"Nimmo","year":"2021","journal-title":"Front Neurosci."},{"key":"10.1016\/j.arr.2024.102229_bib208","article-title":"Effect of masupirdine (SUVN-502) on cognition in patients with moderate Alzheimer's disease: A randomized, double-blind, phase 2, proof-of-concept study","volume":"8","author":"Nirogi","year":"2022","journal-title":"Alzheimers Dement (N\u00a0Y)"},{"key":"10.1016\/j.arr.2024.102229_bib209","doi-asserted-by":"crossref","DOI":"10.3390\/biom13020309","article-title":"Progress in investigational agents targeting serotonin-6 receptors for the treatment of brain disorders","volume":"13","author":"Nirogi","year":"2023","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.arr.2024.102229_bib210","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.nbd.2011.01.021","article-title":"Autophagy failure in Alzheimer\u2019s disease\u2014locating the primary defect","volume":"43","author":"Nixon","year":"2011","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.arr.2024.102229_bib211","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s11011-021-00897-z","article-title":"Effect of curcumin nanoparticles on streptozotocin-induced male Wistar rat model of Alzheimer's disease","volume":"37","author":"Noor","year":"2022","journal-title":"Metab. Brain Dis."},{"key":"10.1016\/j.arr.2024.102229_bib212","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13195-021-00788-6","article-title":"Melatonin levels in the Alzheimer's disease continuum: a systematic review","volume":"13","author":"Nous","year":"2021","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.arr.2024.102229_bib213","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s43587-021-00070-2","article-title":"ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer's disease","volume":"1","author":"Novak","year":"2021","journal-title":"Nat. Aging"},{"key":"10.1016\/j.arr.2024.102229_bib214","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13195-018-0436-1","article-title":"FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer's disease","volume":"10","author":"Novak","year":"2018","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.arr.2024.102229_bib215","article-title":"Current advances in digital cognitive assessment for preclinical Alzheimer's disease","volume":"13","author":"Ohman","year":"2021","journal-title":"Alzheimers Dement (Amst.)"},{"key":"10.1016\/j.arr.2024.102229_bib216","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/jgs.14059","article-title":"Effects of exercise on cognition: the Finnish Alzheimer disease exercise trial: a randomized, controlled trial","volume":"64","author":"Ohman","year":"2016","journal-title":"J. Am. Geriatr. Soc."},{"issue":"625","key":"10.1016\/j.arr.2024.102229_bib217","first-page":"e611","article-title":"Sildenafil ameliorates cognitive deficits and tau pathology in a senescence-accelerated mouse model","volume":"33","author":"Orejana","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.arr.2024.102229_bib218","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.2217\/imt-2016-0019","article-title":"Tau-based therapeutics for Alzheimer's disease: active and passive immunotherapy","volume":"8","author":"Panza","year":"2016","journal-title":"Immunotherapy"},{"key":"10.1016\/j.arr.2024.102229_bib219","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/3245935","article-title":"Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease","volume":"2016","author":"Panza","year":"2016","journal-title":"Biomed. Res Int"},{"key":"10.1016\/j.arr.2024.102229_bib220","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1038\/jcbfm.2012.126","article-title":"Drug transport across the blood-brain barrier","volume":"32","author":"Pardridge","year":"2012","journal-title":"J. Cereb. Blood Flow. Metab."},{"key":"10.1016\/j.arr.2024.102229_bib221","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2119\/molmed.2010.00180","article-title":"Selective antihypertensive dihydropyridines lower Abeta accumulation by targeting both the production and the clearance of Abeta across the blood-brain barrier","volume":"17","author":"Paris","year":"2011","journal-title":"Mol. Med"},{"key":"10.1016\/j.arr.2024.102229_bib222","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s40035-022-00314-0","article-title":"CRISPR\/dCas9-Dnmt3a-mediated targeted DNA methylation of APP rescues brain pathology in a mouse model of Alzheimer's disease","volume":"11","author":"Park","year":"2022","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.arr.2024.102229_bib223","article-title":"Editorial: targets for disease-modifying therapies in alzheimer's disease, including amyloid beta and tau protein","volume":"27","author":"Parums","year":"2021","journal-title":"Med Sci. Monit."},{"key":"10.1016\/j.arr.2024.102229_bib224","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1002\/nop2.878","article-title":"Aducanumab for Alzheimer's disease: the never-ending story that nurses should know","volume":"8","author":"Petch","year":"2021","journal-title":"Nurs. Open"},{"key":"10.1016\/j.arr.2024.102229_bib225","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s00401-018-1903-2","article-title":"Region-specific depletion of synaptic mitochondria in the brains of patients with Alzheimer\u2019s disease","volume":"136","author":"Pickett","year":"2018","journal-title":"Acta neuropathologica"},{"key":"10.1016\/j.arr.2024.102229_bib226","doi-asserted-by":"crossref","DOI":"10.3390\/cells10050969","article-title":"CRISPR-Cas and its wide-ranging applications: from human genome editing to environmental implications, technical limitations, hazards and bioethical issues","volume":"10","author":"Piergentili","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.arr.2024.102229_bib227","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1080\/14728222.2021.1939681","article-title":"The emerging role of the sigma-1 receptor in autophagy: hand-in-hand targets for the treatment of Alzheimer's","volume":"25","author":"Prasanth","year":"2021","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.arr.2024.102229_bib228","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0014-2999(97)01301-0","article-title":"Possible role of nitric oxide-cyclic GMP pathway in object recognition memory: effects of 7-nitroindazole and zaprinast","volume":"337","author":"Prickaerts","year":"1997","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.arr.2024.102229_bib229","doi-asserted-by":"crossref","first-page":"736","DOI":"10.2174\/1871527320666210804155617","article-title":"Melatonin and sleep disturbances in Alzheimer's disease","volume":"20","author":"Prodhan","year":"2021","journal-title":"CNS Neurol. Disord. Drug Targets"},{"issue":"3","key":"10.1016\/j.arr.2024.102229_bib230","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1001\/archneurol.2008.588","article-title":"PGC-1\u03b1 expression decreases in the Alzheimer disease brain as a function of dementia","volume":"66","author":"Qin","year":"2009","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.arr.2024.102229_bib231","first-page":"1","article-title":"5-HT 6 receptors and Alzheimer's disease","volume":"5","author":"Ram\u00edrez","year":"2013","journal-title":"Alzheimer's\u00a0Res. Ther."},{"key":"10.1016\/j.arr.2024.102229_bib232","first-page":"23","article-title":"Sovateltide mediated endothelin B receptors agonism and curbing neurological disorders","author":"Ranjan","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.arr.2024.102229_bib233","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11041131","article-title":"RAGE inhibitors in neurodegenerative diseases","volume":"11","author":"Reddy","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.arr.2024.102229_bib234","doi-asserted-by":"crossref","first-page":"107","DOI":"10.21037\/atm.2016.03.05","article-title":"Toward precision medicine in Alzheimer's disease","volume":"4","author":"Reitz","year":"2016","journal-title":"Ann. Transl. Med"},{"key":"10.1016\/j.arr.2024.102229_bib235","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1001\/jama.299.22.2642","article-title":"Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: a randomized controlled trial","volume":"299","author":"Riemersma-van der Lek","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.arr.2024.102229_bib236","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40478-020-0884-2","article-title":"Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer's disease","volume":"8","author":"Roberts","year":"2020","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.arr.2024.102229_bib237","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jphs.2014.11.011","article-title":"The involvement of the sigma-1 receptor in neurodegeneration and neurorestoration","volume":"127","author":"Ruscher","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.arr.2024.102229_bib238","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.expneurol.2013.07.021","article-title":"Caffeine and modafinil promote adult neuronal cell proliferation during 48h of total sleep deprivation in rat dentate gyrus","volume":"248","author":"Sahu","year":"2013","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.arr.2024.102229_bib239","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1212\/WNL.0000000000012451","article-title":"Aducanumab, amyloid lowering, and slowing of Alzheimer disease","volume":"97","author":"Salloway","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.arr.2024.102229_bib240","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3233\/JAD-190128","article-title":"A pilot study of changes in medial temporal lobe fractional amplitude of low frequency fluctuations after sildenafil administration in patients with Alzheimer's disease","volume":"70","author":"Samudra","year":"2019","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2024.102229_bib241","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3233\/ADR-200166","article-title":"Sildenafil for the treatment of Alzheimer's disease: a systematic review","volume":"4","author":"Sanders","year":"2020","journal-title":"J. Alzheimers Dis. Rep."},{"key":"10.1016\/j.arr.2024.102229_bib242","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1111\/j.1476-5381.2012.02112.x","article-title":"Nimodipine inhibits IL-1beta release stimulated by amyloid beta from microglia","volume":"167","author":"Sanz","year":"2012","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.arr.2024.102229_bib243","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23051068","article-title":"Passive abeta immunotherapy: current achievements and future perspectives","volume":"23","author":"Schilling","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.arr.2024.102229_bib244","doi-asserted-by":"crossref","first-page":"627","DOI":"10.2174\/092986706776055652","article-title":"Pharmacology and physiopathology of the brain endothelin system: an overview","volume":"13","author":"Schinelli","year":"2006","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.arr.2024.102229_bib245","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s00702-006-0579-2","article-title":"The significance of the cholinergic system in the brain during aging and in Alzheimer's disease","volume":"113","author":"Schliebs","year":"2006","journal-title":"J. Neural Transm. (Vienna)"},{"key":"10.1016\/j.arr.2024.102229_bib246","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.neuropharm.2012.07.011","article-title":"Modafinil effects on cognition and emotion in schizophrenia and its neurochemical modulation in the brain","volume":"64","author":"Scoriels","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.arr.2024.102229_bib247","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.1038\/s41467-022-32951-4","article-title":"Structure-based discovery of small molecules that disaggregate Alzheimer's disease tissue derived tau fibrils in vitro","volume":"13","author":"Seidler","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.arr.2024.102229_bib248","doi-asserted-by":"crossref","first-page":"a006189","DOI":"10.1101\/cshperspect.a006189","article-title":"Neuropathological alterations in Alzheimer disease","volume":"1","author":"Serrano-Pozo","year":"2011","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.arr.2024.102229_bib249","article-title":"Alzheimer\u2019s experts greet China\u2019s surprise approval of a drug for brain disease with hope and caution","volume":"5","author":"Servick","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.arr.2024.102229_bib250","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2174\/1570159X19666210823103020","article-title":"PLGA-based curcumin delivery system: an interesting therapeutic approach in the treatment of Alzheimer's disease","volume":"20","author":"Shahbaz","year":"2022","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.arr.2024.102229_bib251","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/7396580","article-title":"Targeting endothelin in Alzheimer's disease: a promising therapeutic approach","volume":"2021","author":"Sharma","year":"2021","journal-title":"Biomed. Res Int"},{"key":"10.1016\/j.arr.2024.102229_bib252","doi-asserted-by":"crossref","first-page":"P1317","DOI":"10.1016\/j.jalz.2017.06.2022","article-title":"[P4\u2013155]: Deriving a cut-off for the elecsys\u00ae \u03b2-amyloid (1\u201342) immunoassay for use in clinical trials supported by eli lilly for patients with clinically defined Alzheimer's disease (AD)","volume":"13","author":"Shaw","year":"2017","journal-title":"Alzheimer'S. Dement."},{"key":"10.1016\/j.arr.2024.102229_bib253","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.3233\/JAD-200227","article-title":"Intranasal dantrolene as a disease-modifying drug in Alzheimer 5XFAD mice","volume":"76","author":"Shi","year":"2020","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2024.102229_bib254","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21176070","article-title":"Nanoparticle-based technology approaches to the management of neurological disorders","volume":"21","author":"Sim","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.arr.2024.102229_bib255","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.ijbiomac.2020.02.041","article-title":"Silymarin encapsulated nanoliquid crystals for improved activity against beta amyloid induced cytotoxicity","volume":"149","author":"Singh","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.arr.2024.102229_bib256","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.brainresbull.2017.02.012","article-title":"Possible role of endothelin receptor against hyperhomocysteinemia and beta-amyloid induced AD type of vascular dementia in rats","volume":"133","author":"Singh","year":"2017","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.arr.2024.102229_bib257","article-title":"Cost-effectiveness of aducanumab to prevent Alzheimer's disease progression at current list price","volume":"8","author":"Sinha","year":"2022","journal-title":"Alzheimers Dement (N\u00a0Y)"},{"key":"10.1016\/j.arr.2024.102229_bib258","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22042153","article-title":"Regenerative stem cell therapy for neurodegenerative diseases: an overview","volume":"22","author":"Sivandzade","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.arr.2024.102229_bib259","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2020.590896","article-title":"New insights into drug discovery targeting tau protein","volume":"13","author":"Soeda","year":"2020","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.arr.2024.102229_bib260","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.bbrc.2018.04.128","article-title":"Sildenafil protects neuronal cells from mitochondrial toxicity induced by beta-amyloid peptide via ATP-sensitive K(+) channels","volume":"500","author":"Son","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.arr.2024.102229_bib261","doi-asserted-by":"crossref","first-page":"4","DOI":"10.6118\/jmm.2017.23.1.1","article-title":"Cell therapy products in Alzheimer disease","volume":"23","author":"Song","year":"2017","journal-title":"J. Menopausa Med"},{"key":"10.1016\/j.arr.2024.102229_bib262","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2305032","article-title":"Trial of solanezumab in preclinical Alzheimer's disease","author":"Sperling","year":"2023","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.arr.2024.102229_bib263","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3389\/fgeed.2020.00004","article-title":"Gene editing and Alzheimer's disease: is there light at the end of the tunnel?","volume":"2","author":"Stepanichev","year":"2020","journal-title":"Front Genome Ed."},{"key":"10.1016\/j.arr.2024.102229_bib264","doi-asserted-by":"crossref","first-page":"5703","DOI":"10.1523\/JNEUROSCI.21-15-05703.2001","article-title":"Generation of aggregated beta-amyloid in the rat hippocampus impairs synaptic transmission and plasticity and causes memory deficits","volume":"21","author":"Stephan","year":"2001","journal-title":"J. Neurosci."},{"key":"10.1016\/j.arr.2024.102229_bib265","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.3390\/molecules25061397","article-title":"Highly bioavailable forms of curcumin and promising avenues for curcumin-based research and application: a review","volume":"25","author":"Stohs","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.arr.2024.102229_bib266","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420935676","article-title":"Diclofenac reduces the risk of Alzheimer's disease: a pilot analysis of NSAIDs in two US veteran populations","volume":"13","author":"Stuve","year":"2020","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.arr.2024.102229_bib267","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s10863-009-9241-7","article-title":"Oxidatively modified, mitochondria-relevant brain proteins in subjects with Alzheimer disease and mild cognitive impairment","volume":"41","author":"Sultana","year":"2009","journal-title":"J. Bioenerg. Biomembr."},{"key":"10.1016\/j.arr.2024.102229_bib268","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.4103\/1673-5374.284994","article-title":"Targeting the transferrin receptor to develop erythropoietin for Alzheimer's disease","volume":"15","author":"Sumbria","year":"2020","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.arr.2024.102229_bib269","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1515\/tnsci-2016-0007","article-title":"The serotonergic system and cognitive function","volume":"7","author":"Svob Strac","year":"2016","journal-title":"Transl. Neurosci."},{"key":"10.1016\/j.arr.2024.102229_bib270","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Abeta protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimers Res Ther."},{"key":"10.1016\/j.arr.2024.102229_bib271","first-page":"CD005379","article-title":"Omega 3 fatty acid for the prevention of cognitive decline and dementia","author":"Sydenham","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.arr.2024.102229_bib272","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s40265-020-01268-1","article-title":"Sodium oligomannate: first approval","volume":"80","author":"Syed","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.arr.2024.102229_bib273","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2017.10.027","article-title":"Nimodipine attenuates tau phosphorylation at Ser396 via miR-132\/GSK-3beta pathway in chronic cerebral hypoperfusion rats","volume":"819","author":"Tan","year":"2018","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.arr.2024.102229_bib274","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.trci.2018.02.002","volume":"4","author":"Tariot","year":"2018","journal-title":"Alzheimers Dement (N. Y)"},{"key":"10.1016\/j.arr.2024.102229_bib275","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14020411","article-title":"Delivery of intravenously administered antibodies targeting Alzheimer's disease-relevant tau species into the brain based on receptor-mediated transcytosis","volume":"14","author":"Tashima","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.arr.2024.102229_bib276","first-page":"663","article-title":"AN-1792 (Elan)","volume":"2","author":"Thatte","year":"2001","journal-title":"Curr. Opin. Invest. Drugs"},{"key":"10.1016\/j.arr.2024.102229_bib277","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0072301","article-title":"Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy","volume":"8","author":"Theunis","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.arr.2024.102229_bib278","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s13167-021-00248-z","article-title":"Endothelin-1 axes in the framework of predictive, preventive and personalised (3P) medicine","volume":"12","author":"Torres Crigna","year":"2021","journal-title":"EPMA J."},{"key":"10.1016\/j.arr.2024.102229_bib279","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s13311-018-0611-x","article-title":"Anti-herpetic medications and reduced risk of dementia in patients with herpes simplex virus infections-a nationwide, population-based cohort study in Taiwan","volume":"15","author":"Tzeng","year":"2018","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.arr.2024.102229_bib280","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/nan.12203","article-title":"Decreased levels of guanosine 3\u2032, 5\u2032-monophosphate (cGMP) in cerebrospinal fluid (CSF) are associated with cognitive decline and amyloid pathology in Alzheimer's disease","volume":"41","author":"Ugarte","year":"2015","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.arr.2024.102229_bib281","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.reth.2020.11.006","article-title":"iPSC for modeling neurodegenerative disorders","volume":"15","author":"Valadez-Barba","year":"2020","journal-title":"Regen. Ther."},{"key":"10.1016\/j.arr.2024.102229_bib282","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2020.101108","article-title":"Exercise benefits on Alzheimer's disease: state-of-the-science","volume":"62","author":"Valenzuela","year":"2020","journal-title":"Ageing Res Rev."},{"key":"10.1016\/j.arr.2024.102229_bib283","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.pharmthera.2013.01.013","article-title":"Immunotherapy for neurodegenerative diseases: focus on alpha-synucleinopathies","volume":"138","author":"Valera","year":"2013","journal-title":"Pharm. Ther."},{"key":"10.1016\/j.arr.2024.102229_bib284","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s13311-015-0397-z","article-title":"Immunotherapeutic Approaches targeting amyloid-beta, alpha-synuclein, and tau for the treatment of neurodegenerative disorders","volume":"13","author":"Valera","year":"2016","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.arr.2024.102229_bib285","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in Early Alzheimer's Disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.arr.2024.102229_bib286","doi-asserted-by":"crossref","first-page":"566","DOI":"10.25259\/JNRP_356_2023","article-title":"Guidelines for pharmacotherapy in Alzheimer\u2019s disease\u2013A primer on FDA-approved drugs","volume":"14","author":"Varadharajan","year":"2023","journal-title":"J. Neurosci. Rural Pract."},{"key":"10.1016\/j.arr.2024.102229_bib287","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1085-9489.2004.009209au.x","article-title":"Endothelin and endothelin-converting-enzyme-1 in inflammatory neuropathies: an immunohistological study","volume":"9","author":"Volpi","year":"2004","journal-title":"J. Peripher. Nerv. Syst."},{"key":"10.1016\/j.arr.2024.102229_bib288","doi-asserted-by":"crossref","first-page":"n1682","DOI":"10.1136\/bmj.n1682","article-title":"Aducanumab for Alzheimer's disease?","volume":"374","author":"Walsh","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.arr.2024.102229_bib289","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.trci.2017.03.005","article-title":"UB-311, a novel UBITh((R)) amyloid beta peptide vaccine for mild Alzheimer's disease","volume":"3","author":"Wang","year":"2017","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.1016\/j.arr.2024.102229_bib290","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3233\/JAD-141506","article-title":"Anti-inflammatory drugs and risk of Alzheimer's disease: an updated systematic review and meta-analysis","volume":"44","author":"Wang","year":"2015","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2024.102229_bib291","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3233\/JAD-160763","article-title":"Role of Glutamate and NMDA Receptors in Alzheimer's Disease","volume":"57","author":"Wang","year":"2017","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2024.102229_bib292","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13195-020-00678-3","article-title":"A phase II randomized trial of sodium oligomannate in Alzheimer's dementia","volume":"12","author":"Wang","year":"2020","journal-title":"Alzheimers Res. Ther."},{"issue":"28","key":"10.1016\/j.arr.2024.102229_bib293","doi-asserted-by":"crossref","first-page":"9090","DOI":"10.1523\/JNEUROSCI.1357-09.2009","article-title":"Impaired balance of mitochondrial fission and fusion in Alzheimer\u2019s disease","volume":"29","author":"Wang","year":"2009","journal-title":"J.\u00a0Neurosci."},{"issue":"49","key":"10.1016\/j.arr.2024.102229_bib294","doi-asserted-by":"crossref","first-page":"19318","DOI":"10.1073\/pnas.0804871105","article-title":"Amyloid-\u03b2 overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission\/fusion proteins","volume":"105","author":"Wang","year":"2008","journal-title":"Proc Natl Acad Sci."},{"key":"10.1016\/j.arr.2024.102229_bib295","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41422-019-0216-x","article-title":"Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer's disease progression","volume":"29","author":"Wang","year":"2019","journal-title":"Cell Res."},{"key":"10.1016\/j.arr.2024.102229_bib296","doi-asserted-by":"crossref","first-page":"E1430","DOI":"10.1503\/cmaj.211134","article-title":"Should Canadian patients look forward to aducanumab for Alzheimer disease?","volume":"193","author":"Watt","year":"2021","journal-title":"CMAJ"},{"key":"10.1016\/j.arr.2024.102229_bib297","article-title":"VALZ-Pilot: High-dose valacyclovir treatment in patients with early-stage Alzheimer's disease","volume":"8","author":"Weidung","year":"2022","journal-title":"Alzheimers Dement (N. Y"},{"key":"10.1016\/j.arr.2024.102229_bib298","first-page":"236","article-title":"Preclinical and clinical development of ABBV-8E12, a humanized anti-tau antibody, for treatment of Alzheimer's disease and other tauopathies","volume":"4","author":"West","year":"2017","journal-title":"J. Prev. Alzheimers Dis."},{"key":"10.1016\/j.arr.2024.102229_bib299","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/path.2449","article-title":"Herpes simplex virus type 1 DNA is located within Alzheimer's disease amyloid plaques","volume":"217","author":"Wozniak","year":"2009","journal-title":"J. Pathol."},{"key":"10.1016\/j.arr.2024.102229_bib300","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1007\/s10072-020-04243-6","article-title":"The efficacy of statins in the treatment of Alzheimer's disease: a meta-analysis of randomized controlled trial","volume":"41","author":"Xuan","year":"2020","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.arr.2024.102229_bib301","doi-asserted-by":"crossref","DOI":"10.6061\/clinics\/2021\/e2348","article-title":"Azeliragon ameliorates Alzheimer's disease via the Janus tyrosine kinase and signal transducer and activator of transcription signaling pathway","volume":"76","author":"Yang","year":"2021","journal-title":"Clinics (Sao Paulo)"},{"key":"10.1016\/j.arr.2024.102229_bib302","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.2147\/IJN.S208332","article-title":"Curcumin-loaded nanoparticles: a novel therapeutic strategy in treatment of central nervous system disorders","volume":"14","author":"Yavarpour-Bali","year":"2019","journal-title":"Int J. Nanomed."},{"key":"10.1016\/j.arr.2024.102229_bib303","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104665","article-title":"Safety, tolerability, immunogenicity, and efficacy of UB-311 in participants with mild Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 2a study","volume":"94","author":"Yu","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.arr.2024.102229_bib304","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/pcn.12637","article-title":"Therapeutic role of rifampicin in Alzheimer's disease","volume":"72","author":"Yulug","year":"2018","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.arr.2024.102229_bib305","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23116080","article-title":"Immunogenicity of MultiTEP-platform-based recombinant protein vaccine, PV-1950R, targeting three B-cell antigenic determinants of pathological alpha-synuclein","volume":"23","author":"Zagorski","year":"2022","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.arr.2024.102229_bib306","doi-asserted-by":"crossref","DOI":"10.1007\/s11064-019-02907-0","article-title":"Pioglitazone attenuates lipopolysaccharide-induced oxidative stress, dopaminergic neuronal loss and neurobehavioral impairment by activating Nrf2\/ARE\/HO-1","author":"Zakaria","year":"2019","journal-title":"Neurochem Res"},{"key":"10.1016\/j.arr.2024.102229_bib307","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1021\/acschemneuro.8b00442","article-title":"Pathological Impacts Of Chronic Hypoxia On Alzheimer's disease","volume":"10","author":"Zhang","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.arr.2024.102229_bib308","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.intimp.2016.12.003","article-title":"PPARgamma activation ameliorates postoperative cognitive decline probably through suppressing hippocampal neuroinflammation in aged mice","volume":"43","author":"Zhang","year":"2017","journal-title":"Int Immunopharmacol."},{"key":"10.1016\/j.arr.2024.102229_bib309","doi-asserted-by":"crossref","first-page":"18325","DOI":"10.1074\/jbc.M117.801514","article-title":"Mechanisms of recognition of amyloid-beta (Abeta) monomer, oligomer, and fibril by homologous antibodies","volume":"292","author":"Zhao","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.arr.2024.102229_bib310","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3233\/JAD-2009-0925","article-title":"Identification of antihypertensive drugs which inhibit amyloid-beta protein oligomerization","volume":"16","author":"Zhao","year":"2009","journal-title":"J. Alzheimers Dis."}],"container-title":["Ageing Research Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568163724000473?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568163724000473?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T17:47:29Z","timestamp":1744480049000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568163724000473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":310,"alternative-id":["S1568163724000473"],"URL":"https:\/\/doi.org\/10.1016\/j.arr.2024.102229","relation":{},"ISSN":["1568-1637"],"issn-type":[{"value":"1568-1637","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolving therapeutic interventions for the management and treatment of Alzheimer\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Ageing Research Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arr.2024.102229","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102229"}}